Autopsy report · NCT02780700

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

“Substance discontinued”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 2 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Boehringer Ingelheim

Sponsor type

Industry

Conditions

Colorectal Neoplasms

Interventions

Nintedanib; Capecitabine

Participants

1

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.